The CPM #10 covering almost the entire skin cancer cell lines included the pharmaceutical agent PLX4720 (vemurafenib) and BRAF mutation; the efficacy of vemurafenib has been tested in several clinical trials for treating unresectable or metastatic melanoma with BRAF V600E mutation (Chapman et al., 2011). Here, BRAF is linked to metastatic melanoma.